Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 5/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | PRCP | P42785 | 1/20 | 0.42 |
| ▸ | CFB | P00751 | 5/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23491401 | 0.86 | RIPK1 (0.40) | RIPK1CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL16474296 | 0.84 | RIPK1 (0.53) | RIPK1P2RX7CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL23491511 | 0.83 | RIPK1 (0.43) | RIPK1P2RX7CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL24493568 | 0.83 | RIPK1 (0.43) | RIPK1P2RX7CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL23491978 | 0.81 | RIPK1 (0.41) | RIPK1P2RX7CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL7833286 | 0.78 | CFB (0.39) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL13407277 | 0.77 | CHRNB2 (0.59) | RIPK1P2RX7CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL6096780 | 0.77 | CHRNB2 (0.59) | RIPK1CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL23423397 | 0.77 | CHRNB2 (0.59) | RIPK1P2RX7CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL23032150 | 0.77 | CHRNB2 (0.59) | RIPK1P2RX7CHRNB2CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210171516-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-06-10 | — | — | US | disclosed |
| US-10787446-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2020-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10787446-B2 | Therapeutic compounds and methods of use thereof | AVPR1B, C3AR1, RHEB | RIPK1 3202/4885P2RX7 433/4885CHRNB2 1972/4885 |
| US-20210171516-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | AVPR1B, C3AR1, RHEB | RIPK1 3202/4885P2RX7 433/4885CHRNB2 1972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.